COVID-19 Clinical Trials

267 recruitingLast updated: June 17, 2026

There are 267 actively recruiting covid-19 clinical trials across 80 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4. Top locations include Houston, Texas, United States, Chicago, Illinois, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


COVID-19 Trials at a Glance

267 actively recruiting trials for covid-19 are listed on ClinicalTrialsFinder across 6 cities in 80 countries. The largest study group is Not Applicable with 72 trials, with the heaviest enrollment activity in Houston, Chicago, and Boston. Lead sponsors running covid-19 studies include National Institute of Allergy and Infectious Diseases (NIAID), M.D. Anderson Cancer Center, and Pfizer.

Browse covid-19 trials by phase

Treatments under study

About COVID-19 Clinical Trials

Looking for clinical trials for COVID-19? There are currently 288 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new COVID-19 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about COVID-19 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 267 trials

Recruiting
Phase 3

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

COVID-19 Infection
Pfizer300 enrolled147 locationsNCT07013474
Recruiting
Phase 3

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

COVID-19 (SARS-CoV-2) infection
Pfizer2,330 enrolled246 locationsNCT06679140
Recruiting

Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection

COVID-19
Centre Hospitalier Universitaire, Amiens300 enrolled1 locationNCT05242159
Recruiting
Phase 1

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

COVID-19
National Institute of Allergy and Infectious Diseases (NIAID)80 enrolled6 locationsNCT07536308
Recruiting
Phase 3

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

Coronavirus Disease (COVID-19)
Merck Sharp & Dohme LLC3,082 enrolled224 locationsNCT06667700
Recruiting

Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.

COVID-19 pneumoniaCardiovascular DiseasesPneumonia, Community-Acquired
Hellenic Institute for the Study of Sepsis650 enrolled18 locationsNCT06601998
Recruiting
Not Applicable

Dietary Intervention to Mitigate Post-Acute COVID-19 Syndrome

FatiguePost-Acute COVID-19 Syndrome
University of Maryland, Baltimore56 enrolled1 locationNCT05977179
Recruiting
Phase 3

sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19

Post COVID-19Post-COVID ConditionsPost-COVID
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)160 enrolled1 locationNCT07359482
Recruiting
Not Applicable

Characterization of the IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19

COVID-19
Hospices Civils de Lyon134 enrolled1 locationNCT06703034
Recruiting

Viral Infections in Healthy and Immunocompromised Hosts

Herpes LabialisCOVID-19Anogenital Herpes
National Institute of Allergy and Infectious Diseases (NIAID)1,000 enrolled1 locationNCT01306084
Recruiting

Long-Term Health Effects of Previous Coronavirus Disease 2019 (COVID-19) in Patients Undergoing Preoperative Anesthesia Evaluation

Long COVIDPost-COVID ConditionSequelae of COVID-19
Elazıg Fethi Sekin Sehir Hastanesi400 enrolled1 locationNCT07435805
Recruiting

The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmCOVID-19 Infection
M.D. Anderson Cancer Center600 enrolled1 locationNCT04551378
Recruiting
Not Applicable

REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval Training for COVID-19

Cardiorespiratory FitnessICU acquired weaknessCOVID-19+2 more
Duke University120 enrolled5 locationsNCT05218083
Recruiting
Not Applicable

Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2

CoronavirusSARS-CoV-2 infectionCOVID-19
Centre Hospitalier Universitaire de Nīmes250 enrolled2 locationsNCT06099795
Recruiting
Phase 4

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations

COVID-19
ModernaTX, Inc.832 enrolled5 locationsNCT07089706
Recruiting
Phase 1

A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.

COVID-19COVID-19 (Prevention)
ModeX Therapeutics, An OPKO Health Company80 enrolled2 locationsNCT07445971
Recruiting
Not Applicable

Analysis of Suicidal Behavior Among Children and Adolescents in the Auvergne-Rhone-Alpes Region During the Covid 19 Pandemic Period

COVID-19Suicidality
Hospices Civils de Lyon6,500 enrolled4 locationsNCT07302295
Recruiting
Phase 3

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

COVID-19Lower Respiratory Tract InfectionImmunocompromised+1 more
Ansun Biopharma, Inc.274 enrolled67 locationsNCT03808922
Recruiting
Phase 1

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

COVID-19
National Institute of Allergy and Infectious Diseases (NIAID)140 enrolled8 locationsNCT07221162
Recruiting

SMAtteo COvid19 REgistry (SMACORE)

COVID-19
Fondazione IRCCS Policlinico San Matteo di Pavia1,000 enrolled1 locationNCT07597876